|Mr. Mark A. Fletcher Esq.||Exec. VP, Gen. Counsel and Sec.||71.46k||N/A||52|
|Dr. Eric von Hofe Ph.D.||VP and Pres of Antigen Express Inc||N/A||N/A||62|
|Mr. Joseph Moscato||Chief Exec. Officer, Pres and Director||N/A||N/A||53|
|Mr. Mark Corrao||Chief Financial Officer and Treasurer||N/A||N/A||60|
|Mr. Andrew Ro||Chief Investment Officer, Sr. VP of Investments and Director||N/A||N/A||46|
Generex Biotechnology Corporation does not have significant business operations. Previously, it was engaged in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. It focused on its proprietary technology for the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator. The company developed Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity using RapidMist hand-held aerosol spray applicator for the treatment of Type 1 and Type 2 diabetes. It also engaged in the development of immunomedicine technology and products for the treatment of breast, prostate, and ovarian cancers; melanoma; influenza; HIV; and autoimmune diseases, such as diabetes and multiple sclerosis. Further, the company offered immunomedicine technology and products, which included immunotherapeutic vaccine AE37 for patients with HER-2/neu positive breast cancer and for patients with prostate cancer; and synthetic peptide vaccines for H5N1 avian influenza and H1N1 swine flu. Generex Biotechnology Corporation was founded in 1983 and is based in Burlington, Canada.
Generex Biotechnology Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.